Litcius/Paper detail

Evaluation of T cell responses with the QuantiFERON SARS-CoV-2 assay in individuals with 3 doses of BNT162b2 vaccine, SARS-CoV-2 infection, or hybrid immunity

Maria-Myrto Dourdouna, Elizabeth‐Barbara Tatsi, Vasiliki Syriopoulou, Athanasios Michos

2023Diagnostic Microbiology and Infectious Disease13 citationsDOIOpen Access PDF

Topics & Concepts

MedicineVaccinationImmunityImmunologyQuantiFERONCellular immunitySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Immune systemCoronavirus disease 2019 (COVID-19)PopulationHerd immunityVirologyELISPOTImmunizationT cellDiseaseTuberculosisInternal medicineInfectious disease (medical specialty)Mycobacterium tuberculosisLatent tuberculosisEnvironmental healthPathologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studiesvaccines and immunoinformatics approaches
Evaluation of T cell responses with the QuantiFERON SARS-CoV-2 assay in individuals with 3 doses of BNT162b2 vaccine, SARS-CoV-2 infection, or hybrid immunity | Litcius